NervGen Pharma Corp.

Recent News

  • NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update

    Vancouver, British Columbia--(Newsfile Corp. - November 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020.Paul Brennan, NervGen's President & CEO, stated, "During this past quarter, we continued working to complete the IND enabling studies necessary to initiate Phase 1 clinical trials for NVG-291 in healthy...

    2020-11-19 8:30 AM ET
  • NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer's Disease Program and Renews Business Advisory Relationship with Brian McAlister

    Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained George Perry, PhD, the current and founding Editor-in-Chief of the Journal of Alzheimer's Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio, to provide independent, expert and multi-disciplinary strategic...

    2020-11-10 8:30 AM ET
  • NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update

    Vancouver, British Columbia--(Newsfile Corp. - October 28, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company's Board of Directors. Separately, NervGen announced that they were advised by its clinical research organization of a logistical delay in obtaining certain materials that are necessary to complete the analysis of...

    2020-10-28 7:30 AM ET
  • NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-Dilutive Funding Sources For NVG-291

    Vancouver, British Columbia--(Newsfile Corp. - October 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Davis, MD, FACS, FRCS (Hon.), Colonel (Ret.), formerly Director of the U.S. Combat Casualty Care Research Program, to help NervGen identify, prioritize and secure sources of non-dilutive funding for developing...

    2020-10-19 7:30 AM ET
  • NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders

    Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple sclerosis, spinal cord injury and Alzheimer's disease. The NVG-291 development program is planned as follows: Phase 1 clinical trial in healthy volunteers remains on track to...

    2020-10-01 6:56 PM ET
  • NervGen Pharma Announces Annual General Meeting and Company Update to Be Held on September 30, 2020

    Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will host its annual general meeting of shareholders (the "AGM") on Wednesday, September 30, 2020 at 2:00 p.m. PDT, as previously advised in the Company's Notice of Meeting filed with the Canadian securities regulatory authorities and posted on...

    2020-09-22 4:26 PM ET
  • NervGen Pharma Announces Departure of Chief Operating Officer

    Vancouver, British Columbia--(Newsfile Corp. - September 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Lloyd Mackenzie has resigned from his position as Chief Operating Officer effective October 2, 2020, in order to assume the President position of a private company not related to the focus of NervGen. The Company also announced that it has...

    2020-09-10 7:30 AM ET
  • NervGen Pharma Reports Second Quarter 2020 Results

    Vancouver, British Columbia--(Newsfile Corp. - August 21, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the second quarter ended June 30, 2020.Paul Brennan, NervGen's President & CEO, stated, "We remain very excited about the potential of our technology to treat nerve damage, whether as a result of an acute injury, such as...

    2020-08-21 7:30 AM ET